SPI Infoamtion

Table of Contents

Executive Summary

Overview of biotech tech transfer
Why biotech tech transfer deals fail
Strategies to ensure successful biotech tech transfer deals
The future of biotech tech transfer deals

Chapter 1 Overview of biotech tech transfer

Summary
The biotechnology industry today

Biotechnology technologies and techniques

Proliferation of investigational products

Funding issues

Need to partner to advance product development

The emergence of biotechnology brokers

Drug development challenges

More complicated disease targets
Escalating costs
Increased regulatory scrutiny
Diminished in-house R&D resources

Types of biotech tech transfer relationships

Academic R&D infusions
Biotech biotech deals
Pharma biotech alliances

Licensing
R&D collaborations
Sales, distribution and co-marketing agreements
Joint ventures
Acquisitions

Volume of recent deals
Relationship trends

Volume and value
Ownership

Conclusion

Chapter 2 Why biotech tech transfer deals fail

Summary
High failure rates

Symptoms of deal failure
Factors that do not affect deal failure

Implications of deal failure

Impact on technology developers
Impact on technology sponsors
Lost value of failed deals

Main causes of biotech tech transfer failure

Due diligence failures

Technology performance
Patent issues
Developer organization strength

Deal structure

Financial compensation

Management changes
Cultural differences
Project organization and expectations
Other preventable problems
Technology failure

Conclusion

Chapter 3 Strategies to ensure successful biotech tech transfer deals

Summary
Measures of success

Success for the technology developer
Success for the technology sponsor

Key biotech tech transfer strategies

Strategies for both technology developers and sponsors

Meeting technology challenges

Strategies for technology developers

Optimizing resources
Thinking like a customer
Working with professional tech transfer organizations
Prolific publishing

Strategies for technology sponsors

Thorough technology identification and due diligence
Structuring innovative deal terms
Addressing compensation issues
Fostering an entrepreneurial developer environment
Ensuring effective alliance management
Navigating cultural chasms
Addressing international intellectual property challenges

Conclusion

Chapter 4 The future of biotech tech transfer deals

Summary
Introduction
The future of drug development

Impact of the economy
US healthcare reform
Biosimilars

Biotechnology in 2010 - 2015

Where biotech fits into Big Pharma
Dedicated biotechnology companies

Biotech tech transfer deal trends 2010 - 2015

Volume and value
Ownership
Intellectual property issues
Success rates

Conclusion

Index

List of Figures
Figure 1.1: Frequency of biotech tech transfer deals by type of institution
Figure 1.2: Number and volume of biopartnering deals, 1997 - 2009
Figure 1.3: Acquisitions as a proportion of biotech tech transfer deals,
Figure 2.4: Characteristics of biotech tech transfer failure causes
Figure 2.5: Relative importance to sponsor of technology developer
Figure 3.6: Strategies to optimize biotech tech transfer opportunities
Figure 4.7: Biopharmaceutical vs. other pharmaceutical sales, 2009 - 2015
Figure 4.8: Impact of industry and economic trends on conventional and biotech drug developers, 2009 - 2015
Figure 4.9: Relative importance of biotechnology for leading pharmaceutical companies, 2009 vs. 2015
Figure 4.10: Number and average size of global biotech companies, 2009 - 2015
Figure 4.11: Number and volume of biopartnering deals, 2009 - 2015

List of Tables
Table 1.1: Definition of biotechnology techniques
Table 1.2: Biotech tech transfer deals, 2009
Table 1.3: Biotech tech transfer deals, 2009 (Contd.)
Table 1.4: Biotech tech transfer deals, 2009 (Contd.)
Table 1.5: Biotech tech transfer deals, 2009 (Contd.)
Table 1.6: Biotech tech transfer deals, 2009 (Contd.)
Table 1.7: Biotech tech transfer deals, 2009 (Contd.)
Table 1.8: Biotech tech transfer deals, 2009 (Contd.)
Table 1.9: Biotech tech transfer deals, 2009 (Contd.)
Table 1.10: Biotech tech transfer deals, 2009 (Contd.)
Table 1.11: Biotech tech transfer deals, 2009 (Contd.)
Table 1.12: Biotech tech transfer deals, 2009 (Contd.)
Table 1.13: Biotech tech transfer deals, 2009 (Contd.)
Table 1.14: Biotech tech transfer deals, 2009 (Contd.)
Table 1.15: Biotech tech transfer deals, 2009 (Contd.)
Table 1.16: Biotech tech transfer deals, 2009 (Contd.)
Table 3.17: Technology transfer areas of interest for Merck & Co., 2010
Table 3.18: Technology transfer areas of interest for Merck & Co., 2010 (Contd.)
Table 3.19: Novartis private equity fund holdings, 2010
Table 3.20: Novartis private equity fund holdings, 2010 (Contd.)
Table 3.21: Novartis private equity fund holdings, 2010 (Contd.)
Table 3.22: Novartis private equity fund holdings, 2010 (Contd.)
Table 4.23: Millions of older and overweight persons in the US and EU, 2009 - 2015
Table 4.24: Biosimilars approved in the US and EU, 2010